Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.
Wolthuis DFGJ et al.
European Journal of Human Genetics : Ejhg, 2025
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Assessing the Performance of In silico Tools and Molecular Dynamics Simulations for Predicting Pharmacogenetic Variant Impact.
AlSaeed MJ et al.
Clinical Pharmacology and Therapeutics, 2024
Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
Parikh SJ et al.
Journal of Inorganic Biochemistry, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
Manson LEN et al.
European Journal of Human Genetics : Ejhg, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Beyond Single Diagnosis: Exploring Multidiagnostic Realities in Pediatric Patients through Genome Sequencing.
Guo F et al.
Human Mutation, 2024
Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen.
Yuan LJ et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.
Zhou Y et al.
Human Genomics, 2023
Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects.
Zhang Q et al.
Frontiers in Endocrinology, 2023
Pharmacogenomic implications of the differential distribution of CYP2C9 metabolic phenotypes among Latin American populations.
Suarez-Kurtz G
Frontiers in Pharmacology, 2023
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Ethnic Diversity and Warfarin Pharmacogenomics.
Asiimwe IG et al.
Frontiers in Pharmacology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population.
Zhao FL et al.
Frontiers in Pharmacology, 2022
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A et al.
Journal of Thrombosis and Haemostasis : Jth, 2021
Pharmacogenetic determinants of warfarin in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2021
Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison.
Parikh SJ et al.
International Journal of Molecular Sciences, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.
Kumondai M et al.
Journal of Personalized Medicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
El Rouby N et al.
Clinical and Translational Science, 2020
Analysis of protein missense alterations by combining sequence- and structure-based methods.
Gyulkhandanyan A et al.
Molecular Genetics & Genomic Medicine, 2020
Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen.
Manish M et al.
Computational Biology and Chemistry, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF et al.
Drug Design, Development and Therapy, 2020
Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.
Claudio-Campos K et al.
Pharmacogenomics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age- vs. Genotype-Related Differences.
Dücker CM et al.
Clinical Pharmacology and Therapeutics, 2019
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T et al.
Genetic Testing and Molecular Biomarkers, 2019
Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy.
Shah M et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2019
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Kasi PM et al.
Technology in Cancer Research & Treatment, 2019
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
Claudio-Campos KI et al.
Pharmacogenomics, 2019
Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.
Ndadza A et al.
Omics : a Journal of Integrative Biology, 2019
Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution.
Arendse LB et al.
Scientific Reports, 2018
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
Kubo K et al.
The Pharmacogenomics Journal, 2017